Transcenta, headquartered in China and with a pipeline of over ten therapeutic antibody candidates, is a clinical-stage biopharmaceutical company with expertise in biologics discovery, translational research, clinical, and process development. The post Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology appeared first on GEN - Genetic Engineering …
Alongside decisions involving capacity expansion, officials at Samsung Biologics announced that the company is pursuing opportunities to broaden its portfolio and address an increasingly diverse range of therapeutic modalities. The post Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm appeared first on GEN - Genetic Engineering and Biotechnology News .
A new extracellular secretion system could help biopharmaceutical manufacturers bypass the problems that make traditional Escherichia coli-based recombinant endonuclease production a major challenge, according to the authors of a new study. The post Extracellular Secretion System Could Solve Industry Endonuclease Production Challenges appeared first on GEN - Genetic Engineering and Biotechnology …
Andrew Zydney, Bayard D. Kunkle Chair and professor of chemical engineering at Penn State, is part of a team whose project, "Inline Spiking Method for Validation of Virus Clearance in Continuous Bioprocessing," has been selected as the inaugural recipient of the National Institute for Innovation in Biopharmaceutical Manufacturing Most Impactful Project Award.
